Curated News
By: NewsRamp Editorial Staff
June 11, 2025
Silo Pharma Secures Key Patent for PTSD Treatment, Advances Clinical Trials
TLDR
- Silo Pharma's new patent for SPC-15 enhances its competitive edge in developing innovative treatments for stress-induced disorders, positioning it ahead in the biopharmaceutical industry.
- The U.S. Patent and Trademark Office will issue Silo Pharma a patent for biomarkers evaluating prophylactic treatments, marking a step forward in methodical research for PTSD therapies.
- Silo Pharma's advancement in PTSD and stress-induced disorder treatments promises a brighter future for patients suffering from these challenging conditions, improving mental health care globally.
- Discover how Silo Pharma's intranasal PTSD treatment, backed by a new patent, could revolutionize mental health therapies with its innovative approach to drug delivery.
Impact - Why it Matters
This development is crucial as it represents a significant advancement in the treatment of stress-induced affective disorders, including PTSD, a condition affecting millions worldwide. Silo Pharma's innovative approach, particularly with SPC-15, could offer a new, effective treatment option, addressing a critical unmet need in mental health care. The company's progress underscores the potential of psychedelic and novel therapeutics in transforming psychiatric treatment paradigms.
Summary
Silo Pharma (NASDAQ: SILO) has achieved a significant milestone with the U.S. Patent and Trademark Office issuing a Notice of Allowance for its licensed patent application concerning biomarkers for evaluating treatments for stress-induced affective disorders. This patent, U.S. Patent No. 12,329,726, is a cornerstone for Silo Pharma's intellectual property, particularly for its lead candidate, SPC-15, an innovative intranasal PTSD treatment developed in collaboration with Columbia University. CEO Eric Weisblum highlighted the patent's NIH backing as a pivotal step as the company gears up for Phase 1 clinical trials of SPC-15. Silo Pharma is at the forefront of developing novel therapeutics for underserved conditions, including stress-induced psychiatric disorders and chronic pain, with a portfolio that includes SP-26 for fibromyalgia and chronic pain, and preclinical programs SPC-14 and SPU-16 targeting Alzheimer's disease and multiple sclerosis, respectively. For more details, visit https://ibn.fm/m86OT.
PsychedelicNewsWire (PNW), part of the Dynamic Brand Portfolio @ IBN, serves as a vital communications platform for the psychedelics sector, offering comprehensive services to enhance brand awareness and reach. PNW's extensive network and tailored solutions provide unparalleled opportunities for companies like Silo Pharma to connect with investors, consumers, and the general public. Discover more at PsychedelicNewsWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Secures Key Patent for PTSD Treatment, Advances Clinical Trials
